Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Recent and upcoming data on axi-cel for patients with NHL

Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, talks on the approval of axicabtagene ciloleucel (axi-cel) for the treatment of patients with non-Hodgkin lymphoma (NHL), highlighting data at four years of follow-up which has demonstrated around 40% control of large B-cell lymphomas. Prof. Jäger also comments on the benefits of using axi-cel in earlier lines of therapy. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.